People and Business News — 6/22
People News
WCG has appointed Sam Srivastava as Chief Executive Officer; Robert VanHees as Chief Financial and Administrative Officer; and Paul Mancinelli, PhD, as Chief Technology Officer.
mdgroup has charged its new VP, Product Delivery, Mohamad (Mo) Merhi with doubling the development team, and appointed LaQuinta Jernigan to Chief Operating Officer.
Dotmatics announced the additions of Larry Samuelson as Chief Legal Officer and Neil Frye as Chief People Officer.
AeroSafe Global announced Jessica Cao joined the company as Senior Vice President of Marketing.
Allucent, announced the appointment of Katy Moore as President of Clinical Pharmacology, Modeling and Simulation.
Walgreens announced several new hires including Kendal Whitlock as Head of Digital Optimization, RWE Clinical Trials; John Campbell as Head of Decentralized Clinical Trials; Liam Wood as Head of Product, RWE Clinical Trials, and Adam Samson as Head of Clinical Delivery Operations, RWE Clinical Trials.
Recognition
Vitalograph is celebrating 21 years as a clinical trials service provider.
mdgroup has been shortlisted as one of the UK's fastest-growing private companies in the inaugural Sunday Times 100 ranking.
For the seventh consecutive year, Celerion has been named recipient of the Life Science Leader and Clinical Leader’s CRO Leadership Awards in all five award categories.
Talvey Plus Tecvayli Shows Promising Results in Multiple Myeloma but Raises Infection Concerns
January 9th 2025A Phase Ib/II dose escalation and expansion trial shows promising antitumor activity and durable responses with Talvey (talquetamab) plus Tecvayli (teclistamab) in the treatment of relapsed or refractory multiple myeloma, but a higher incidence of grade 3 or 4 infections.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
Rybrevant Plus Lazcluze Shows Over One-Year Survival Boost in EGFR-Mutated NSCLC Patients
January 7th 2025Results from the Phase III MARIPOSA trial demonstrated the combination of Rybrevant (amivantamab-vmjw) and Lazcluze (lazertinib) significantly improves overall survival compared to the current standard of care, Tagrisso (osimertinib), for patients with EGFR-mutated advanced or metastatic non-small cell lung cancer.
